Intelligence Feed event · Equity · 2026-08-03

    Curium to Acquire Lantheus in $8 Billion Radiopharmaceutical Deal

    Question

    Curium to Acquire Lantheus in $8 Billion Radiopharmaceutical Deal

    Direct answer

    The $102.50 cash offer provides an immediate valuation anchor for Lantheus. The inclusion of CVRs suggests ongoing value in the pipeline that Curium is willing to pay for if specific targets are met. This deal highlights the increasing M&A activity in specialized healthcare sectors as larger players seek to dominate niche diagnostic markets.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Curium to Acquire Lantheus in $8 Billion Radiopharmaceutical Deal”, revision 1, evidence through 2026-08-03. https://marketontology.com/market-events/2026-08-03/curium-to-acquire-lantheus-in-8-billion-radiopharmaceutical-deal-9941d6

    EQUITY
    Curium to Acquire Lantheus in $8 Billion Radiopharmaceutical Deal
    The $102.50 cash offer provides an immediate valuation anchor for Lantheus. The inclusion of CVRs suggests ongoing value in the pipeline that Curium is willing to pay for if specific targets are met. This deal highlights the increasing M&A activity in specialized healthcare sectors as larger players seek to dominate niche diagnostic markets.
    LNTH
    Impact
    81
    AUG 3
    SIG
    100%
    LNTH
    Curium to Acquire Lantheus in $8 Billion Radiopharmaceutical Deal
    The $102.50 cash offer provides an immediate valuation anchor for Lantheus. The inclusion of CVRs suggests ongoing value in the pipeline that Curium is willing to pay for if specific targets are met. This deal highlights the increasing M&A activity in specialized healthcare sectors as larger players seek to dominate niche diagnostic markets.
    → Direct equity price floor via cash acquisition price.
    Impact
    The $102.50 cash offer provides an immediate valuation anchor for Lantheus. The inclusion of CVRs suggests ongoing value in the pipeline that Curium is willing to pay for if specific targets are met. This deal highlights the increasing M&A activity in specialized healthcare sectors as larger players seek to dominate niche diagnostic markets.
    Affected
    LNTH
    Transmission
    Direct equity price floor via cash acquisition price.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month